Seres Therapeutics and Société des Produits Nestlé S.A. amended their August 2024 asset purchase agreement to terminate Nestlé's obligations for second and third sales milestone payments and related interest accruals. The modification reduces Seres' potential future contingent payments from the product asset sale.